Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 2/20 | 0.47 |
| ▸ | MGMT | P16455 | 1/20 | 0.36 |
| ▸ | MIF | P14174 | 2/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29410061 | 0.84 | NAAA (0.59) | NAAAMIFTRPA1 | |
| SCHEMBL31373160 | 0.82 | MGMT (0.43) | MGMT | |
| SCHEMBL31373165 | 0.82 | MGMT (0.43) | MGMT | |
| SCHEMBL31373162 | 0.82 | MGMT (0.43) | MGMT | |
| SCHEMBL31373088 | 0.82 | MGMT (0.43) | MGMT | |
| SCHEMBL13434049 | 0.82 | MGMT (0.43) | MGMT | |
| SCHEMBL14211649 | 0.82 | MGMT (0.43) | MGMT | |
| SCHEMBL31758954 | 0.82 | MGMT (0.43) | MGMT | |
| SCHEMBL13650682 | 0.82 | MGMT (0.43) | MGMT | |
| SCHEMBL18858998 | 0.82 | MGMT (0.43) | MGMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250090643-A1 | FUNCTIONALIZED BIOCATALYTICAL COMPOSITIONS | PERSEO PHARMA AG (CH) | 2025-03-20 | — | — | US | disclosed |
| EP-4466024-A1 | FUNCTIONALIZED BIOCATALYTICAL COMPOSITIONS | Perseo Pharma AG (CH) | 2024-11-27 | — | — | EP | disclosed |
| CN-118574645-A | Functionalized biocatalytic compositions | 佩尔西奥制药公司 | 2024-08-30 | — | — | CN | disclosed |
| WO-2023139150-A1 | FUNCTIONALIZED BIOCATALYTICAL COMPOSITIONS | PERSEO PHARMA AG (CH) | 2023-07-27 | — | — | WO | disclosed |
| EP-2788354-B1 | FUNCTIONALISATION OF CAGE AMINE LIGANDS FOR METALLO-RADIOPHARMACEUTICALS | UNIV MELBOURNE (AU) | 2016-11-30 | — | — | EP | disclosed |
| US-9364570-B2 | Functionalisation of cage amine ligands for metallo-radiopharmaceuticals | THE UNIVERSITY OF MELBOURNE (AU) | 2016-06-14 | — | — | US | disclosed |
| US-20150051392-A1 | FUNCTIONALISATION OF CAGE AMINE LIGANDS FOR METALLO-RADIOPHARMACEUTICALS | THE UNIVERSITY OF MELBOURNE (AU) | 2015-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051392-A1 | FUNCTIONALISATION OF CAGE AMINE LIGANDS FOR METALLO-RADIOPHARMACEUTICALS | SLC39A14, AOC1, RNF168 | NAAA 2191/4885MGMT 10/4885MIF 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.